Also forgot to add, the Company Secretary did mention that they do not their cost of production yet and hence all figures (65% profit margin) is an estimate. They are currently doing a costing exercise and would know about their costs only in the next month or so.
They have also asked their Accountants (Kendalls) to provide them with a tax planning strcture so that they can aviod the 55% tax rates in Russia. Any sales of Ropren will happen only after that. The negotiations with regards to the pricing is going on at the moment with the Dept of Health and it will take some time for them to announce a price but they have based their numbers on a min price of $10000. They will break even next financial year and once the Tomsk facility is in operation they should see revenues in excess of $200MM.
SLA Price at posting:
67.3¢ Sentiment: Buy Disclosure: Held
